{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:31:18Z","timestamp":1775233878792,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T00:00:00Z","timestamp":1529452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00417-018-4042-5","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T19:33:28Z","timestamp":1529436808000},"page":"1801-1806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections"],"prefix":"10.1007","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-0539","authenticated-orcid":false,"given":"Ebru Nevin","family":"Cetin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6nder","family":"Demirta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nihal Cesur","family":"\u00d6zbak\u0131\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6khan","family":"Pekel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,20]]},"reference":[{"issue":"1","key":"4042_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcjo.2012.11.012","volume":"48","author":"BJ Thomas","year":"2003","unstructured":"Thomas BJ, Shienbaum G, Boyer DS et al (2003) Evolving strategies in the management of diabetic macular edema: clinical trials and current management. Can J Ophthalmol 48(1):22\u201330","journal-title":"Can J Ophthalmol"},{"issue":"6","key":"4042_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4239\/wjd.v4.i6.310","volume":"4","author":"C Krispel","year":"2013","unstructured":"Krispel C, Rodrigues M, Xin X et al (2013) Ranibizumab in diabetic macular edema. World J Diabetes 4(6):310\u2013318","journal-title":"World J Diabetes"},{"issue":"3","key":"4042_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3928\/23258160-20150304-01","volume":"46","author":"CC Wykoff","year":"2015","unstructured":"Wykoff CC, Hariprasad SM (2015) Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR protocol T. Ophthalmic Surg Lasers Imaging Retina 46(3):302\u2013305","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"2","key":"4042_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1001\/jamaophthalmol.2015.4599","volume":"134","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Jampol LM et al (2016) Diabetic retinopathy clinical research network. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. JAMA Ophthalmol 134(2):127\u2013134","journal-title":"JAMA Ophthalmol"},{"key":"4042_CR5","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","volume":"117","author":"QD Nguyen","year":"2010","unstructured":"Nguyen QD, Shah SM, Khwaja AA et al (2010) READ-2 study group. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 117:2146\u20132151","journal-title":"Ophthalmology"},{"key":"4042_CR6","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2337\/dc10-0493","volume":"33","author":"P Massin","year":"2010","unstructured":"Massin P, Bandello F, Garweg JG et al (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:2399\u20132405","journal-title":"Diabetes Care"},{"issue":"12","key":"4042_CR7","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1097\/IAE.0000000000000349","volume":"34","author":"SC Bu","year":"2014","unstructured":"Bu SC, Kuijer R, Li XR et al (2014) Idiopathic epiretinal membrane. Retina 34(12):2317\u20132335","journal-title":"Retina"},{"issue":"9","key":"4042_CR8","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1167\/iovs.10-6781","volume":"52","author":"A Ophir","year":"2011","unstructured":"Ophir A, Martinez MR (2011) Epiretinal membranes and incomplete posterior vitreous detachment in diabetic macular edema, detected by spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 52(9):6414\u20136420","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"4042_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/eye.2010.80","volume":"24","author":"A Ophir","year":"2010","unstructured":"Ophir A, Martinez MR, Mosqueda P et al (2010) Vitreous traction and epiretinal membranes in diabetic macular oedema using spectral-domain optical coherencetomography. Eye (Lond) 24(10):1545\u20131553","journal-title":"Eye (Lond)"},{"issue":"3","key":"4042_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0002-9394(01)01050-9","volume":"132","author":"T Yamamoto","year":"2001","unstructured":"Yamamoto T, Akabane N, Takeuchi S (2001) Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 132(3):369\u2013377","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"4042_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ajo.2007.07.012","volume":"144","author":"NG Ghazi","year":"2007","unstructured":"Ghazi NG, Ciralsky JB, Shah SM et al (2007) Optical coherence tomography findings in persistent diabetic macular edema: the vitreomacular interface. Am J Ophthalmol 144(5):747\u2013754","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"4042_CR12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","volume":"130","author":"SB Bressler","year":"2012","unstructured":"Bressler SB, Qin H, Beck RW et al (2012) Diabetic retinopathy clinical research network. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol 130(9):1153\u20131161","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"4042_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s10792-013-9884-6","volume":"34","author":"D Yoon","year":"2014","unstructured":"Yoon D, Rusu I, Barbazetto I (2014) Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities. Int Ophthalmol 34(4):817\u2013823","journal-title":"Int Ophthalmol"},{"issue":"2","key":"4042_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/ceo.12374","volume":"43","author":"M Zhang","year":"2015","unstructured":"Zhang M, Chu S, Zeng F et al (2015) Bevacizumab modulates the process of fibrosis in vitro. Clin Exp Ophthalmol 43(2):173\u2013179","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"4042_CR15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/bjophthalmol-2011-300141","volume":"96","author":"A Ramasubramanian","year":"2012","unstructured":"Ramasubramanian A, Shields CL (2012) Bevacizumab for Coats\u2019 disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol 96(3):356\u2013359","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"4042_CR16","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/eye.2014.13","volume":"28","author":"P Osaadon","year":"2014","unstructured":"Osaadon P, Fagan XJ, Lifshitz T et al (2014) A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond) 28(5):510\u2013520","journal-title":"Eye (Lond)"},{"issue":"7","key":"4042_CR17","doi-asserted-by":"publisher","first-page":"e2675","DOI":"10.1371\/journal.pone.0002675","volume":"3","author":"EJ Kuiper","year":"2008","unstructured":"Kuiper EJ, Van Nieuwenhoven FA, de Smet MD et al (2008) The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One 3(7):e2675","journal-title":"PLoS One"},{"key":"4042_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-2415-14-51","volume":"14","author":"JW Kim","year":"2014","unstructured":"Kim JW, Choi KS (2014) Quantitative analysis of macular contraction in idiopathic epiretinal membrane. BMC Ophthalmol 14:51","journal-title":"BMC Ophthalmol"},{"issue":"7","key":"4042_CR19","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S0161-6420(99)10164-7","volume":"106","author":"D Weinberger","year":"1999","unstructured":"Weinberger D, Stiebel-Kalish H, Priel E et al (1999) Digital red-free photography for the evaluation of retinal blood vessel displacement in epiretinal membrane. Ophthalmology 106(7):1380\u20131383","journal-title":"Ophthalmology"},{"issue":"7","key":"4042_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/eye.2013.99","volume":"27","author":"K Kawano","year":"2013","unstructured":"Kawano K, Ito Y, Kondo M et al (2013) Displacement of foveal area toward optic disc after macular hole surgery with internal limiting membrane peeling. Eye (Lond) 27(7):871\u2013877","journal-title":"Eye (Lond)"},{"issue":"4","key":"4042_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00417-016-3562-0","volume":"55","author":"Y Wong","year":"2017","unstructured":"Wong Y, Steel DHW, Habib MS, Stubbing-Moore A, Bajwa D, Avery PJ (2017) Sunderland eye infirmary study group. Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol 55(4):733\u2013742","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"4042_CR22","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/eye.2016.317","volume":"31","author":"CK Chang","year":"2017","unstructured":"Chang CK, Cheng CK, Peng CH (2017) The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF. Eye (Lond) 31(5):762\u2013770","journal-title":"Eye (Lond)"},{"issue":"1","key":"4042_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/ICB.0b013e3181578dd8","volume":"3","author":"ME Torres-Soriano","year":"2009","unstructured":"Torres-Soriano ME, Reyna-Castel\u00e1n E, Hern\u00e1ndez-Rojas M et al (2009) Tractional retinal detachment after intravitreal injection of bevacizumab in proliferative diabetic retinopathy. Retin Cases Brief Rep 3(1):70\u201373","journal-title":"Retin Cases Brief Rep"},{"key":"4042_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/bjo.2007.127142","volume":"92","author":"JF Arevalo","year":"2008","unstructured":"Arevalo JF, Maia M, Flynn HW Jr et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213\u2013216","journal-title":"Br J Ophthalmol"},{"key":"4042_CR25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.ophtha.2008.11.005","volume":"116","author":"Y Oshima","year":"2009","unstructured":"Oshima Y, Shima C, Wakabayashi T et al (2009) Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 116:927\u2013938","journal-title":"Ophthalmology"},{"issue":"7","key":"4042_CR26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1096\/fj.03-1273rev","volume":"18","author":"A Leask","year":"2004","unstructured":"Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18(7):816\u2013827","journal-title":"FASEB J"},{"issue":"1","key":"4042_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2337\/db06-0581","volume":"56","author":"T Kita","year":"2007","unstructured":"Kita T, Hata Y, Kano K et al (2007) Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of rho kinase inhibitor. Diabetes 56(1):231\u2013238","journal-title":"Diabetes"},{"issue":"10","key":"4042_CR28","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1001\/archopht.124.10.1457","volume":"124","author":"EJ Kuiper","year":"2006","unstructured":"Kuiper EJ, de Smet MD, van Meurs JC et al (2006) Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol 124(10):1457\u20131462","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"4042_CR29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/ndt\/15.3.296","volume":"15","author":"R Goldschmeding","year":"2000","unstructured":"Goldschmeding R, Aten J, Ito Y et al (2000) Connective tissue growth factor: just another factor in renal fibrosis. Nephrol Dial Transplant 15(3):296\u2013299","journal-title":"Nephrol Dial Transplant"},{"issue":"9402","key":"4042_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0140-6736(03)15172-0","volume":"363","author":"B Perbal","year":"2004","unstructured":"Perbal B (2004) CCN proteins: multifunctional signaling regulators. Lancet 363(9402):62\u201364","journal-title":"Lancet"},{"issue":"1","key":"4042_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/ndt\/gfh570","volume":"20","author":"FA Nieuwenhoven van","year":"2005","unstructured":"van Nieuwenhoven FA, Jensen LJ, Flyvbjerg A et al (2005) Imbalance of growth factor signaling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point. Nephrol Dial Transplant 20(1):6\u201310","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"4042_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2147\/CIA.S135364","volume":"26","author":"SA Kabanarou","year":"2017","unstructured":"Kabanarou SA, Xirou T, Mangouritsas G et al (2017) Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration. Clin Interv Aging 26(12):911\u2013915","journal-title":"Clin Interv Aging"},{"issue":"2","key":"4042_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1755-3768.2008.01226.x","volume":"87","author":"G Querques","year":"2009","unstructured":"Querques G, Souied EH, Soubrane G (2009) Macular hole following intravitreal ranibizumab injection for choroidal neovascular membrane caused by age-related macular degeneration. Acta Ophthalmol 87(2):235\u2013237","journal-title":"Acta Ophthalmol"},{"issue":"43 Online","key":"4042_CR34","first-page":"e87","volume":"30","author":"FC Erdurman","year":"2012","unstructured":"Erdurman FC, Pellumbi A, Durukan AH (2012) Lamellar macular hole formation in a patient with diabetic CME treated by intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 30(43 Online):e87\u2013e89","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"8","key":"4042_CR35","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ophtha.2015.04.028","volume":"122","author":"CE Veloso","year":"2015","unstructured":"Veloso CE, Kanadani TM, Pereira FB et al (2015) Vitreomacular Interface after anti-vascular endothelial growth factor injections in Neovascular age-related VMacular degeneration. Ophthalmology 122(8):1569\u20131572","journal-title":"Ophthalmology"},{"issue":"7","key":"4042_CR36","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00417-013-2266-y","volume":"251","author":"U Geck","year":"2013","unstructured":"Geck U, Pustolla N, Baraki H et al (2013) Posterior vitreous detachment following intravitreal drug injection. Graefes Arch Clin Exp Ophthalmol 251(7):1691\u20131695","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-018-4042-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-4042-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-4042-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T19:10:19Z","timestamp":1560971419000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-018-4042-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,20]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["4042"],"URL":"https:\/\/doi.org\/10.1007\/s00417-018-4042-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,20]]},"assertion":[{"value":"28 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}